Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation
Main finding · Myocardial infarction risk, modified early-risk participantsResult — go to the resultHazard ratio 0.87 95% CI 0.81–0.95Authors' conclusion
Among adults with dyslipidemia who received prescriptions covering a total of 180 days, statin-ezetimibe combination therapy was associated with a lower subsequent risk of myocardial infarction than statin monotherapy across modified CKM risk groups. The association was most evident in moderate-intensity comparisons.
Study context
- Population
- Adults aged 30–74 years with dyslipidemia who received prescriptions covering a total of 180 days with statin monotherapy or a fixed-dose statin-ezetimibe combination, Korean National Health Insurance Service database239,954 (modified early risk) · 69,417 (modified late risk)
- Participants
- 309,371 treated participants
- Comparison
- Statin-ezetimibe therapy vs statin monotherapy, treatment assigned at the 180-day landmark
- Outcome
- Myocardial infarction risk, modified early-risk participants
Methodological detailsseparate two-arm landmark target trials within modified early and late cardiovascular-kidney-metabolic risk groups, stabilized inverse probability of treatment weighting, cause-specific Cox regression, death treated as a competing event for cumulative incidence estimation
- Separate two-arm landmark target trials within modified early and late cardiovascular-kidney-metabolic risk groups
- Stabilized inverse probability of treatment weighting
- Cause-specific Cox regression
- Death treated as a competing event for cumulative incidence estimation
Main finding
As reported in the abstract
Myocardial infarction risk, modified early-risk participants
Hazard ratio
0.87
95% CI 0.81–0.95
Statin-ezetimibevs Statin monotherapy
HR 0.87 (95% CI 0.81–0.95)
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Myocardial infarction risk, modified late-risk participantsAfter weighting | 0.88 (0.79–0.98) | |
| Myocardial infarction, same-intensity comparison, moderate-intensity therapy, early CKM groupAssociation most evident with moderate-intensity therapy | 0.87 (0.79–0.95) | |
| 0.512Hazard ratio (log scale) |
Myocardial infarction, 10-year weighted cumulative incidence, early-risk and late-risk groups
- Weighted cumulative incidence reported for each risk group; the abstract does not state which value belongs to which treatment group
Original publication
Statin–Ezetimibe Therapy and Incident Myocardial Infarction Across Modified Cardiovascular–Kidney–Metabolic Risk Groups: A Nationwide Target Trial Emulation. Eur Heart J Cardiovasc Pharmacother. Published 13 November 2026. doi:10. 1093/ ehjcvp/ pvag099
Composed by AI from the published abstract and checked against it. How Briefs are made →